With this fortuitous distinction, it became possible to deliver a potent TLR7 agonist to tumor resident Tregs without altering their properties elsewhere, leading to a ~40-80% reduction in tumor growth without inducing obvious systemic toxicities. This evidence concerns the gene TLR7 and neoplasm.